🟢 Citius Pharmaceuticals is trading 10.4% up today after reporting 78% growth in new LYMPHIR accounts

Citius Pharmaceuticals is trading at $0.69 (+10.39%) after reporting significant commercial momentum for LYMPHIR through its oncology subsidiary.

• The company achieved 78% quarterly growth in new accounts, supported by higher vial orders and increased institutional account traction.
• While the stock is benefiting from a broader risk-on tape and a firmer healthcare sector, the primary driver is the company’s specific commercial update.
• The report highlights accelerating adoption of LYMPHIR, which appears to be the clearest catalyst for today's price appreciation.